Join the Tirzepatide group to help and get support from people like you.
Tirzepatide News (Page 4)
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
MONDAY, Jan. 13, 2025 – For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with...
Some GLP-1s Achieve More Weight Loss Than Others: Study
WEDNESDAY, Jan. 8, 2025 – Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. A new evidence review published ...
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
TUESDAY, Jan. 7, 2025 – For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published...
FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first and only...
FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
THURSDAY, Dec. 19, 2024 – The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over....
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
FRIDAY, Nov. 22, 2024 – For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart...
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
MONDAY, Nov. 18, 2024 – For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes,...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
FDA Medwatch Alert: FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness
November 1, 2024 – FDA is warning patients and health care professionals not to use drugs compounded and distributed by Fullerton Wellness LLC, Ontario, Calif., and distributed to patients by...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome, Diabetes, Type 2